Compare GRPN & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | SLDB |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2011 | 2017 |
| Metric | GRPN | SLDB |
|---|---|---|
| Price | $21.36 | $9.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $33.67 | $16.36 |
| AVG Volume (30 Days) | ★ 1.6M | 957.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,843,877,000.00 | $8,094,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $6.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.17 | $3.79 |
| 52 Week High | $29.90 | $11.45 |
| Indicator | GRPN | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 36.07 | 58.39 |
| Support Level | $15.97 | $6.25 |
| Resistance Level | $22.39 | $11.45 |
| Average True Range (ATR) | 1.68 | 0.44 |
| MACD | -0.89 | 0.10 |
| Stochastic Oscillator | 2.39 | 96.27 |
Groupon Inc is a globalised, scaled two-sided marketplace that connects consumers to merchants. Its categories include Local: local inventory includes things to do, beauty and wellness, food and drink, home and automotive services, online services, as well as other types of experiences and services. Goods: Includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel, and Travel: Features travel experiences at both discounted and market rates, including hotels, airfare, and package deals covering both domestic and international travel. The company operates in two segments, North America and International, with the majority of revenue from the Local category from the North America Segment.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.